

MOLSIDOMINE INHIBITS THE CHEMOATTRACTANT-INDUCED RESPIRATORY BURST IN HUMAN NEUTROPHILS VIA A NO-INDEPENDENT MECHANISM

JÜRGEN ERVENS and ROLAND SEIFERT*

Institut für Pharmakologie, Freie Universität Berlin, Thielallee 69/73, D-1000 Berlin 33, Germany

(Received 5 August 1991; accepted 5 June 1992)

Abstract—3-Morpholino-sydnominine (SIN-1) is a NO-releasing compound which mimics the effects of cGMP through activation of soluble guanylyl cyclase. Its prodrug, molsidomine (SIN-10), does not release NO but does modulate various cell functions. These findings prompted us to study the effects of SIN-10 and SIN-1 on the respiratory burst in human neutrophils. SIN-10 was more effective than SIN-1 in inhibiting superoxide anion (O_2^-) formation induced by *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu-Phe) and by C5a. The effects of SIN-1 and SIN-10 on O_2^- formation were additive or less than additive, indicating the sydnominines acted through a common mechanism. The sydnominines showed no effect on O_2^- formations induced by γ -hexachlorocyclohexane, arachidonic acid and a phorbol ester. They did not inhibit O_2^- formation induced by xanthine oxidase, by autoxidation of pyrogallol and in a cell-free system from HL-60 leukemic cells. Neutrophils did not convert SIN-10 to SIN-1 as assessed by O_2 consumption which accompanies NO release from SIN-1. The cell-permeant analogue of cGMP, *N*²,2'-*O*-dibutyryl guanosine 3':5'-monophosphate (Bt₂cGMP), and SIN-10 but not SIN-1 inhibited fMet-Leu-Phe-induced O_2 consumption. SIN-1 and SIN-10 slightly enhanced agonist binding to formyl peptide receptors, whereas Bt₂cGMP was inhibitory. The sydnominines did not affect GTP hydrolysis of heterotrimeric regulatory guanine nucleotide-binding proteins in HL-60 membranes. SIN-1 but not SIN-10 stimulated ADP-ribosylation of a 39-kDa protein in the cytosol of HL-60 cells. SIN-10 reduced fMet-Leu-Phe-induced rises in cytosolic Ca^{2+} concentration in neutrophils. These data suggest that SIN-10 inhibits the respiratory burst via a NO-independent mechanism which may involve inhibition of rises in cytosolic Ca^{2+} concentration.

In human neutrophils, the chemoattractants, *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu-Phe[†]) and complement C5a, induce β -glucuronidase release from azurophilic granules and a respiratory burst [1–4]. The latter process is catalysed by NADPH oxidase [EC 1.6.99.6] and is characterized by O_2 consumption and superoxide anion (O_2^-) formation [1–4]. Formyl peptide and C5a receptors interact with heterotrimeric guanine nucleotide-binding proteins (G-proteins), resulting in the stimulation of phospholipase C with subsequent activation of protein kinase C and rises in cytosolic Ca^{2+} concentration ($[Ca^{2+}]_i$) [1, 2, 4]. The mechanisms by which chemoattractants activate the respiratory burst are still a matter of debate and may involve activation of G-proteins, low molecular mass GTP-binding proteins, protein kinase C and rises in $[Ca^{2+}]_i$ [1, 2, 4].

Recent data suggest that cGMP plays a role in the regulation of β -glucuronidase release and the respiratory burst, as its cell-permeant analogue, *N*²,2'-*O*-dibutyryl guanosine 3':5'-monophosphate (Bt₂cGMP), inhibits enzyme release and O_2^- formation induced by fMet-Leu-Phe and potentiates those induced by C5a [5–7]. Neutrophils possess a cGMP-forming soluble guanylyl cyclase [8], a cGMP-dependent protein kinase [9] and a cGMP-degrading phosphodiesterase [10]. Guanylyl cyclase is activated by the NO-releasing compounds, sodium nitroprusside (SNP) and 3-morpholino-sydnominine (SIN-1) [11–13]. In agreement with the above data, SNP and SIN-1 increase cGMP levels in neutrophils [5]. Additionally, NO-releasing compounds activate ADP-ribosylation of a 39-kDa protein and modulate various cell functions in a cGMP-independent manner [14–18]. Similar to other cell types, neutrophils generate NO [19–21], and NO-releasing compounds mimic, in part, the effects of Bt₂cGMP on chemoattractant-induced β -glucuronidase release [5, 7].

SIN-10 is a prodrug and is converted to SIN-1 in the liver [12, 22]. Accordingly, SIN-10 does not increase cGMP levels in neutrophils [5]. Surprisingly, SIN-10 inhibits β -glucuronidase release in neutrophils more effectively than SIN-1 [5, 7]. Interestingly, an analogue of SIN-10 induces vasodilation, indicating that this substance does not only serve as a prodrug for a NO-releasing substance but is a

* Corresponding author. Tel. (49) 30 838 2064; FAX (49) 30 831 5954.

† Abbreviations: Bt₂cAMP, *N*⁶,2'-*O*-dibutyryl adenosine 3':5'-monophosphate; Bt₂cGMP, *N*²,2'-*O*-dibutyryl guanosine 3':5'-monophosphate; $[Ca^{2+}]_i$, cytosolic Ca^{2+} concentration; fMet-Leu-Phe, *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine; G-protein, heterotrimeric regulatory guanine nucleotide-binding protein; HCCH, γ -hexachlorocyclohexane; O_2^- , superoxide anion; PMA, phorbol myristate acetate; SIN-1, 3-morpholino-sydnominine; SIN-10, molsidomine; SNP, sodium nitroprusside.

pharmacologically active substance *per se* [23]. All these data prompted us to study the effects of SIN-1 and SIN-10 on the respiratory burst in human neutrophils. We report here that SIN-10 inhibits the chemottractant-induced respiratory burst via a NO-independent mechanism.

MATERIALS AND METHODS

Materials. SIN-1 and SIN-10 were kindly provided by Cassella (Frankfurt/Main, Germany). Stock solutions of SIN-1 (100 mmol/L) and SIN-10 (50 mmol/L) were prepared in 100 and 50 mmol/L Na-acetate, pH 5.0, immediately prior to use under light protection. Xanthine, xanthine oxidase [EC 1.2.3.2] (grade III, from buttermilk), superoxide dismutase (lyophilized powder, from bovine erythrocytes) [EC 1.15.1.1], ferricytochrome *c* (type III, from horse heart), SNP, pyrogallol, antimycin, dithiothreitol and epinephrine were purchased from Sigma Chemie (Deisenhofen, Germany). The preparation of ferricytochrome *c* used for the experiments in the present study contained up to 10% (w/w) ferrocytochrome *c*. Stock solutions of SNP were prepared as described for SIN-1. Pyrogallol (10 mmol/L) was dissolved in 10 mmol/L HCl immediately prior to use. Sources of other materials have been described elsewhere [6, 7, 24–28].

Isolation of human neutrophils. Neutrophils were isolated from buffy coat obtained from the local blood bank or from individual healthy volunteers [6, 7, 24]. Cell preparations consisted of more than 95% viable neutrophils as revealed by Trypan blue dye exclusion and Pappenheim-stained smears.

Cell culture. HL-60 cells were cultured in suspension culture as described [24, 25, 27]. HL-60 cells were differentiated towards neutrophil-like cells upon incubation with 160 mmol/L dimethyl sulfoxide for 120 hr or with 0.2 mmol/L Bt₂cAMP for 48 hr [24, 25, 27]. HL-60 membranes and cytosol were prepared as described [25].

O₂⁻ formation in intact human neutrophils. O₂⁻ formation was monitored at 550 nm by continuous measurement of ferricytochrome *c* reduction inhibitable by superoxide dismutase [24]. Preliminary experiments revealed that SIN-1 and SIN-10 did not inhibit superoxide dismutase (data not shown). Reaction mixtures (0.5 mL) contained 100 µmol/L ferricytochrome *c* and a buffer consisting of (mmol/L) 138 NaCl, 6 KCl, 1 MgCl₂, 1 CaCl₂, 5.5 glucose and 20 Hepes–NaOH, pH 7.4. Neutrophils (2.0 × 10⁶ cells) were suspended in the solution described above and were incubated for 3 min in the presence of various substances at 37°. O₂⁻ formation was initiated by the addition of stimuli. In the experiments with fMet-Leu-Phe, C5a, HCCH and arachidonic acid, the absolute amounts of O₂⁻ generated within an incubation period of 5 min were calculated. Within this time, O₂⁻ formation ceased completely. In the experiments with phorbol myristate acetate (PMA), the maximum rate of O₂⁻ formation, which was achieved within 5 min of addition of the stimulus, was calculated.

O₂⁻ formation in a cell-free system from dimethyl sulfoxide-differentiated HL-60 cells. O₂⁻ formation was monitored at 550 nm by continuous measurement

of ferricytochrome *c* reduction inhibitable by superoxide dismutase. Reaction mixtures (0.5 mL) contained 50 µg membrane protein, 150 µg cytosolic protein, 10 µmol/L FAD, 500 µmol/L NADPH, 100 µmol/L ferricytochrome *c*, 2 mmol/L MgCl₂, 20 mmol/L KH₂PO₄, 40 mmol/L KCl and 20 mmol/L triethanolamine/HCl, pH 7.0. Reaction mixtures were incubated for 3 min at 25° in the presence of various compounds. O₂⁻ formation was initiated by the addition of arachidonic acid (200 µmol/L) [25]. The maximum rate of O₂⁻ formation, which was achieved within 5 min of the addition of arachidonic acid, was calculated.

O₂⁻ formation by xanthine oxidase. O₂⁻ was generated by xanthine oxidase-catalysed conversion of xanthine to uric acid. O₂⁻ formation was monitored at 550 nm by continuous measurement of ferricytochrome *c* reduction inhibitable by superoxide dismutase [29]. Reaction mixtures (0.5 mL) contained xanthine (50 µmol/L), ferricytochrome *c* (100 µmol/L) and a buffer composed of 50 mmol/L KH₂PO₄ and 0.1 mmol/L EDTA, pH 7.8. Assays were conducted at 25°. Reactions were initiated by the addition of an amount of xanthine oxidase that induced the formation of 1.25 nmol of O₂⁻/min. O₂⁻ formation was monitored for the first 3 min after addition of the enzyme.

O₂⁻ formation by pyrogallol. O₂⁻ was generated by autooxidation of pyrogallol [30]. O₂⁻ formation was monitored at 550 nm by continuous measurement of ferricytochrome *c* reduction inhibitable by superoxide dismutase under the conditions used for the determination of O₂⁻ formation in intact neutrophils. Reaction mixtures were incubated for 3 min in the presence of various substances at 37°. O₂⁻ formation was initiated by the addition of pyrogallol (30 µmol/L). Pyrogallol induced the formation of 3.5 nmol of O₂⁻. Within 5 min, O₂⁻ formation was terminated.

Effects of SIN-10 and SIN-1 on redox state of cytochrome *c*. Under the experimental conditions used for measurement of O₂⁻ formation in intact neutrophils, in a cell-free system from HL-60 cells, by xanthine oxidase and by pyrogallol, SIN-10 and SIN-1 up to 1 mmol/L *per se* did not induce O₂⁻ formation or oxidation of ferrocytochrome *c* present in the commercial preparation. SIN-10 and SIN-1 (0.1 and 1 mmol/L each) showed no oxidative effects on ferricytochrome *c* reductions induced by dithiothreitol (0.1 mmol/L) or epinephrine (1 mmol/L), regardless of whether sydnonimines were added to reaction mixtures 3 min prior to or 3 min after the reducing substances. In addition, SIN-10 and SIN-1 (0.1 and 1 mmol/L each) did not induced reoxidation of cytochrome *c* that was completely reduced by dithiothreitol or epinephrine.

O₂ consumption in intact human neutrophils. O₂ consumption was measured using a Biometer O₂ electrode (Braun, Melsungen, Germany) according to the protocol described by Absolom [3]. Neutrophils (3 × 10⁷ cells) were suspended at 37° in 3 mL of the buffer used for the determination of O₂⁻ formation in intact cells supplemented with antimycin (10 µmol/L) and cytochalasin B (1 µg/mL). Cells were stirred at 500 rpm. O₂ consumption was measured in the presence of various compounds.

fMet-Leu-Phe binding assay. fMet-Leu-Phe binding was performed as described [26]. Reaction mixtures (100 μ L) contained 40 μ g of membrane protein from Bt₂cAMP-differentiated HL-60 cells, bovine serum albumin (0.2%, w/v), 50 mmol/L Tris-HCl, pH 7.3, 1 mmol/L EDTA and 5 mmol/L MgCl₂ in the presence of various substances. Incubations were conducted for 30 min at 25° and were initiated by the addition of 3 nmol/L fMet-Leu-[³H]Phe (17 nCi/tube). Reactions were terminated by the rapid filtration technique. Radioactivity on dried filters was determined in a liquid scintillation counter. Unspecific binding was determined in the presence of 10 μ mol/L fMet-Leu-Phe and amounted to less than 10% of total binding.

Measurement of GTPase activity. GTP hydrolysis was measured as described [27]. Assay mixtures (100 μ L) contained membranes from Bt₂cAMP-differentiated HL-60 cells (7.0 μ g of protein/tube), 0.5 μ mol/L [γ -³²P]GTP (0.1 μ Ci/tube), 5 mmol/L MgCl₂, 0.1 mmol/L EGTA, 0.1 mmol/L ATP, 1 mmol/L adenosine 5'-[β , γ -imido]-triphosphate, 5 mmol/L creatine phosphate, 40 μ g of creatine kinase, 1 mmol/L dithiothreitol and 0.2% (w/v) bovine serum albumin in 50 mmol/L triethanolamine-HCl, pH 7.4. Reaction mixtures contained various additional substances. Reactions were initiated by the addition of [γ -³²P]GTP and were conducted for 15 min at 25°. Low-affinity GTPase activity was determined in the presence of GTP (50 μ mol/L) and amounted to <5% of total GTPase activity.

[³²P]ADP-ribosylation of proteins in cytosol from HL-60 cells and gel electrophoresis. [³²P]ADP-ribosylation of cytosolic proteins from dimethyl sulfoxide-differentiated HL-60 cells was performed according to Dimmeler and Brüne [15]. Briefly, assay mixtures (60 μ L) contained 100 μ g of cytosolic proteins, 1 μ mol/L [³²P]NAD (2 μ Ci/tube), 2 mmol/L dithiothreitol and 0.2% (w/v) bovine serum albumin in 50 mmol/L HEPES-NaOH, pH 7.5. Assays contained various additional substances. Incubations were conducted for 45 min at 37°. Thereafter, proteins were precipitated by acetone. Precipitates were washed with trichloroacetic acid and subsequently with methanol-chloroform (1:2, v/v). Proteins were resolved by SDS-PAGE on gels containing 12.5% (w/v) acrylamide. Staining of dried gels with Coomassie blue and autoradiography were performed as described [28].

Measurement of [Ca²⁺]_i. [Ca²⁺]_i was determined using the fluorescent dye, Fura-2, as described [7, 26]. Neutrophils were suspended at 5 \times 10⁶ cells/mL in a buffer consisting of (mmol/L) 138 NaCl, 6 KCl, 1 MgSO₄, 1.1 CaCl₂, 0.1 EGTA, 1 Na₂HPO₄, 5 NaHCO₃, 5.5 glucose, 20 HEPES-NaOH, pH 7.4, supplemented with bovine serum albumin (0.1%, w/v). Cells were incubated for 1 hr at 37° in the presence of Fura-2-acetoxymethyl ester (4 μ mol/L). Subsequently, cells were diluted with the above buffer to a final concentration of 0.5 \times 10⁶ cells/mL and were centrifuged for 10 min at 250 g at 20°. Cells were suspended at 1.0 \times 10⁶ cells/mL in the above buffer and were kept at 20° until measurement of [Ca²⁺]_i. Fluorescence of neutrophils (1.0 \times 10⁶ cells in 2 mL) was determined at 37° under constant

stirring at 10³ rpm using a Ratio II spectrofluorometer (Aminco, Silver Spring, MD, U.S.A.). Cells were incubated for 3 min in the presence of SIN-10 or solvent prior to the addition of fMet-Leu-Phe. The excitation and emission wavelengths were 340 and 500 nm, respectively.

Miscellaneous. Protein was determined according to Lowry *et al.* [31]. [γ -³²P]GTP was synthesized according to Johnson and Walseth [32]. [³²P]NAD was prepared as described [33]. The effects of sydnonimines were statistically assessed using the Wilcoxon test.

RESULTS

First, the effects of sydnonimines on O₂⁻ formation in intact human neutrophils were studied. Sydnonimines were employed at concentrations ranging from 3 μ mol/L to 1 mmol/L, i.e. concentrations commonly used in various systems [5, 7, 12, 14, 18, 22-34]. SIN-10 and SIN-1 inhibited fMet-Leu-Phe-induced O₂⁻ formation in a concentration-dependent manner (Fig. 1). SIN-10 was considerably more effective than SIN-1. The solvent Na-acetate did not inhibit O₂⁻ formation.

The interaction of sydnonimines with fMet-Leu-Phe-induced O₂⁻ formation was studied (Fig. 2). SIN-1 (1 mmol/L) enhanced additively the inhibitory effect of SIN-10 (0.1 mmol/L) on O₂⁻ formation. However, under various other conditions, the inhibitory effects of SIN-1 and SIN-10 were not additive.




Fig. 1. Concentration dependency of the effects of SIN-10, SIN-1 and Na-acetate on fMet-Leu-Phe-induced O₂⁻ formation in human neutrophils. Compounds at the indicated concentrations were added to reaction mixtures 3 min prior to fMet-Leu-Phe (1 μ mol/L). In the presence of H₂O (control), fMet-Leu-Phe induced the formation of 5.1 \pm 0.3 nmol of O₂⁻/10⁶ cells. Data shown are referred to these values and are the means of five independent experiments; the SD values of the data were generally <15% of the means. The open circles indicate that substances at the indicated concentrations did not inhibit O₂⁻ formation. (▲) SIN-10; (▼) SIN-1; (●) Na-acetate. The inhibitory effects of SIN-10 and SIN-1 on O₂⁻ formation versus control were significant at 0.1, 0.3 and 1 mmol/L and at 0.3 and 1 mmol/L, respectively (P < 0.05 or P < 0.01).




Fig. 2. Interaction of SIN-10 and SIN-1 on fMet-Leu-Phe-induced O₂⁻ formation in human neutrophils. Compounds at various concentrations were added to reaction mixtures 3 min prior to fMet-Leu-Phe (1 µmol/L). 1, solvent (control); 2, SIN-1 (1 mmol/L); 3, SIN-10 (1 mmol/L); 4, SIN-1 plus SIN-10 (1 mmol/L each); 5, SIN-1 (0.1 mmol/L); 6, SIN-10 (0.1 mmol/L); 7, SIN-1 plus SIN-10 (0.1 mmol/L each); 8, SIN-1 (1 mmol/L) plus SIN-10 (0.1 mmol/L); 9, SIN-1 (0.1 mmol/L) plus SIN-10 (1 mmol/L). Data shown are the means ± SD of four independent experiments.

Table 1 compares the effects of SIN-10 and SIN-1 on O₂⁻ formation in neutrophils induced by various stimuli. In the presence of fMet-Leu-Phe at a submaximally effective concentration, SIN-10 and SIN-1 inhibited O₂⁻ formation to similar extents as did fMet-Leu-Phe at a maximally effective concentration. By analogy to fMet-Leu-Phe, SIN-10 was more effective than SIN-1 in inhibiting C5a-induced O₂⁻ formation. In contrast, SIN-10 and SIN-1 did not affect O₂⁻ formation induced by HCCH, arachidonic acid and PMA, i.e. stimuli which circumvent receptor stimulation.

In a cell-free system from HL-60 cells, arachidonic

acid induced the formation of O₂⁻ at a rate of 20 nmol of O₂⁻/min/mg of membrane protein. Guanosine 5'-O-(3-thiotriphosphate) (10 µmol/L), an activator of G-proteins and low molecular mass GTP-binding proteins [2], enhanced this O₂⁻ formation by about 3.5-fold (data not shown) [25]. SIN-10 and SIN-1 (1 mmol/L each) did not inhibit O₂⁻ formation in this system (data not shown).

Radical scavenging may explain inhibition by NO of NADPH oxidase-catalysed O₂⁻ formation [35]. Therefore, the effects of SIN-10 and SIN-1 on O₂⁻ formation in systems unrelated to NADPH oxidase were assessed. SIN-10 and SIN-1 (1 mmol/L each)

Table 1. Effects of SIN-10 and SIN-1 on O₂⁻ formation in human neutrophils induced by various stimuli

Stimulus	O ₂ ⁻ formation (% of control)	
	SIN-10	SIN-1
fMet-Leu-Phe (20 nmol/L)	13†	60†§
fMet-Leu-Phe (1 µmol/L)	20†	73†§
C5a (10 nmol/L)	34†	77†§
HCCH (125 µmol/L)	105*	96*‡
Arachidonic acid (20 µmol/L)	97*	95*‡
PMA (100 ng/mL)	98*	97*‡

SIN-10 or SIN-1 (1 mmol/L each) or solvent (control) was added to reaction mixtures 3 min prior to stimuli. Data shown are referred to O₂⁻ formations induced by substances in the presence of solvent and are the means of six independent experiments; the SD values of the data were generally < 15% of the means. In the presence of solvent, fMet-Leu-Phe (20 nmol/L) and (1 µmol/L) induced the formation of 1.7 ± 0.3 and 5.3 ± 0.4 nmol of O₂⁻/10⁶ cells, respectively. The corresponding values for C5a, HCCH and arachidonic acid were 1.3 ± 0.1, 1.8 ± 0.2 and 1.9 ± 0.2 nmol of O₂⁻/10⁶ cells, respectively. PMA induced the formation of 10.5 ± 0.2 nmol of O₂⁻/min/10⁶ cells. Comparison of the effects of compounds versus control: * not significant; † P < 0.01. Comparison of the effects of SIN-10 versus SIN-1: ‡ not significant; § P < 0.01.




Fig. 3. Effects of SIN-10, SIN-1, Bt₂cAMP and Bt₂cGMP on O₂ consumption in human neutrophils. O₂ consumption was measured at 37° using an O₂ electrode. Assays contained 3×10^7 neutrophils each. In the experiments shown in panel A, sydnonimines were added to cells at $t = 0$ min. In the experiments shown in panels B and C, fMet-Leu-Phe was added to cells at $t = 0$ min; sydnonimines, Bt₂cAMP, Bt₂cGMP or solvent (control) was added to reaction mixtures 3 min prior to fMet-Leu-Phe. Panel A: trace 1, SIN-10 (1 mmol/L); trace 2, SIN-1 (0.1 mmol/L); trace 3, SIN-1 (1 mmol/L). Panel B: trace 1, fMet-Leu-Phe (50 nmol/L) plus solvent (control) or fMet-Leu-Phe (1 μ mol/L) plus SIN-10 (1 mmol/L); trace 2, fMet-Leu-Phe (1 μ mol/L) plus SIN-10 (0.3 mmol/L); trace 3, fMet-leu-Phe (1 μ mol/L) plus solvent (control) or SIN-10 (0.1 mmol/L); trace 4, fMet-Leu-Phe (50 nmol/L) plus SIN-1 (1 mmol/L). Panel C: trace 1, fMet-Leu-Phe (50 nmol/L) plus Bt₂cGMP (1 mmol/L); trace 2, fMet-Leu-Phe (50 nmol/L) plus Bt₂cAMP (1 mmol/L); trace 3, fMet-Leu-Phe (1 μ mol/L) plus Bt₂cAMP (1 mmol/L); trace 4, fMet-Leu-Phe (50 nmol/L) plus solvent (control); trace 5, fMet-Leu-Phe (1 μ mol/L) plus solvent (control) or Bt₂cGMP (1 mmol/L). Superimposed original tracings from one experiment are shown. Similar results were obtained in five independent experiments.

showed no effect on xanthine oxidase-catalysed O₂⁻ formation (data not shown). Additionally, sydnonimines (1 mmol/L each) did not inhibit pyrogallol-induced O₂⁻ formation (data not shown).

Release of NO from SIN-1 is associated with O₂ consumption [22]. In order to answer the question as to whether neutrophils convert SIN-10 to SIN-1, O₂ consumption in the presence of sydnonimines and cells was studied. SIN-10 did not induce O₂ consumption (Fig. 3). By contrast, SIN-1 (0.1 and 1 mmol/L) induced substantial O₂ consumption. SIN-10 (0.3 and 1 mmol/L) significantly inhibited fMet-Leu-Phe-induced O₂ consumption (see Fig. 3). Similar to O₂⁻ formation, SIN-10 did not inhibit O₂ consumption induced by PMA (100 ng/mL) (see Table 1, data not shown). SIN-1 enhanced fMet-Leu-Phe-induced O₂ consumption in an additive manner. For comparison with sydnonimines, the effects of N⁶,2'-O-dibutyryl adenosine 3':5'-cyclic monophosphate (Bt₂cAMP) and Bt₂cGMP on fMet-Leu-Phe-induced O₂ consumption were studied (see Fig. 3). As was the case for O₂⁻ formation [6], Bt₂cGMP was more effective than Bt₂cAMP in inhibiting O₂ consumption stimulated by fMet-Leu-Phe at a submaximally effective concentration. Bt₂cAMP but not Bt₂cGMP inhibited O₂ consumption induced by fMet-Leu-Phe at a maximally effective concentration.

In order to study the mechanism by which

sydnonimines inhibit the chemoattractant-induced respiratory burst, their effects on agonist binding to formyl peptide receptors and on high-affinity GTPase activity of G-proteins in HL-60 membranes were studied (Table 2). Sydnonimines enhanced agonist binding by up to 17%, whereas Bt₂cGMP inhibited fMet-Leu-Phe binding by 32%. Bt₂cAMP was less inhibitory than Bt₂cGMP. None of the above substances showed an effect on high-affinity GTP hydrolysis (see Table 2).

The effects of sydnonimines and of SNP on ADP-ribosylation of a 39-kDa protein in the cytosol of HL-60 cells are shown in Fig. 4. In agreement with the results of a recent study, we found that SNP stimulates ADP-ribosylation of the 39-kDa substrate in the cytosol of these cells [15]. SIN-1 was more effective than SNP in inducing ADP-ribosylation of this protein. In comparison, SIN-10 induced little, if any ADP-ribosylation of the 39-kDa protein.

Finally, the effects of SIN-10 on [Ca²⁺]_i were studied. SIN-10 (10 μ mol/L) did not affect basal [Ca²⁺]_i in human neutrophils (Table 3). However, the sydnonimine inhibited rises in [Ca²⁺]_i induced by fMet-Leu-Phe at a submaximally and maximally effective concentration by more than 30%. Unfortunately, the effects of SIN-10 at higher concentrations on [Ca²⁺]_i could not be quantitatively assessed as the sydnonimine quenched basal fluorescence signals (data not shown).

Table 2. Effects of SIN-10, SIN-1, Bt₂cAMP and Bt₂cGMP on agonist binding to formyl peptide receptors and on high-affinity GTPase activity in HL-60 membranes

Addition	fMet-Leu-Phe binding (fmol/mg protein)	GTP hydrolysis (pmol P _i /mg/min)
Solvent (control)	598 ± 23	25.6 ± 0.8
SIN-10 (1 mmol/L)	676 ± 38†	25.9 ± 0.3*
SIN-1 (1 mmol/L)	700 ± 42†	26.1 ± 1.0*
Bt ₂ cAMP (1 mmol/L)	520 ± 18†	25.5 ± 0.9*
Bt ₂ cGMP (1 mmol/L)	407 ± 19‡	24.8 ± 1.1*

fMet-Leu-Phe binding to formyl peptide receptors and high-affinity GTPase activity of G-proteins in membranes from Bt₂cAMP-differentiated HL-60 cells were measured in the presence of various substances at the indicated concentrations or solvent (control) under the conditions described in Materials and Methods. Data shown are the means ± SD of three experiments performed in quadruplicate each. Comparison of the effects of compounds versus control: * not significant; † P < 0.05; ‡ P < 0.01.

DISCUSSION

SIN-10 is the prodrug of the NO-releasing substance, SIN-1 [12, 22]. Somewhat unexpectedly, we found that SIN-10 very effectively inhibits the fMet-Leu-Phe-induced respiratory burst in human neutrophils (see Figs 1–3 and Table 1). In agreement with these data, fMet-Leu-Phe-induced β -glucuronidase release is substantially inhibited by SIN-10 [5, 7]. The lack of synergism between SIN-10 and SIN-1 in the inhibition of fMet-Leu-Phe-induced O₂⁻ formation indicates that sydnonimines act through a common mechanism (see Fig. 2).

Several data suggest that sydnonimines inhibit the respiratory burst through a mechanism which is independent of NO release with subsequent activation of soluble guanylyl cyclase and increase in cGMP. First, SIN-10 was considerably more effective than SIN-1 in inhibiting fMet-Leu-Phe-induced O₂⁻ formation (see Figs 1 and 2). Second, SIN-10 substantially inhibited fMet-Leu-Phe-induced O₂ consumption, whereas SIN-1 did not (see Fig. 3). Third, neutrophils did not convert SIN-10 to SIN-1, as the former substance did not induce O₂ consumption, a process which accompanies the release of NO from SIN-1 (see Fig. 3) [22]. In agreement with these data is the finding that SIN-10 does not increase cGMP levels in human neutrophils [5]. Additionally, SIN-10 did not mimic the effects of Bt₂cGMP on the respiratory burst. Specifically, sydnonimines inhibited the effects of fMet-Leu-Phe at a submaximally and maximally effective concentration on the respiratory burst, whereas Bt₂cGMP only inhibited O₂⁻ formation and O₂ consumption induced by fMet-Leu-Phe at a submaximally effective concentration (see Figs 1–3 and Table 3) [6]. Finally, sydnonimines inhibited C5a-induced O₂⁻ formation, whereas Bt₂cGMP potentiated the effects of C5a (see Table 1) [6].

What may be the mechanism by which sydnonimines




Fig. 4. Effects of SIN-10, SIN-1 and SNP on ADP-ribosylation of a 39-kDa protein in cytosol from dimethyl sulfoxide-differentiated HL-60 cells. Cytosolic proteins from dimethyl sulfoxide-differentiated HL-60 cells (100 μ g/tube) were incubated for 45 min in the presence of [³²P]-NAD and various substances. Proteins were analysed as described in Materials and Methods. The autoradiogram of a Coomassie blue-stained gel is shown. Lane 1, SIN-10 (1 mmol/L); lane 2, solvent (control); lane 3, SNP (1 mmol/L); lane 4, SIN-1 (1 mmol/L). Numbers on the left represent molecular masses of marker proteins (kDa); DF, dye front. Similar results were obtained in three experiments.

Table 3. Effects of SIN-10 and SIN-1 on fMet-Leu-Phe-induced rises in [Ca²⁺]_i in human neutrophils

Stimulus	Increase in [Ca ²⁺] _i (nmol/L)	
	Control	(SIN-10)
fMet-Leu-Phe (1 nmol/L)	487 ± 47	326 ± 50*
fMet-Leu-Phe (10 nmol/L)	955 ± 32	628 ± 38*

Cells were loaded with Fura-2 acetoxymethylester and the increases in [Ca²⁺]_i induced by fMet-Leu-Phe at the indicated concentrations were determined. SIN-10 (10 μ mol/L) or solvent (control) were added to reaction mixtures 3 min prior to fMet-Leu-Phe. Basal [Ca²⁺]_i in control and SIN-10-treated cells was 149 ± 10 nmol/L and 145 ± 5 nmol/L, respectively. Data shown are the means ± SD of five experiments. Comparison of the effects of SIN-10 versus control: * P < 0.05.

inhibit the chemoattractant-induced respiratory burst? Under the conditions employed, the sydnonimines did not interfere with the detection method for O_2^- formation (see Materials and Methods). Additionally, these substances did not reoxidize ferrocycytochrome *c* (see Materials and Methods). Moreover, the sydnonimines did not scavenge O_2^- as is supported by their lack of effect on xanthine oxidase-catalysed and pyrogallol-induced O_2^- formation and on receptor-independent activation of O_2^- formation in intact neutrophils and in a cell-free system from HL-60 cells (see Table 1). Furthermore, SIN-10 inhibited not only fMet-Leu-Phe-induced O_2^- formation, but also fMet-Leu-Phe-induced O_2 consumption (see Figs 1 and 3).

As the radical-scavenging properties of sydnonimines are unlikely to account for their inhibitory effects on the respiratory burst, we studied their effects on various steps of the signal transduction cascade in human myeloid cells. Sydnonimines specifically interfered with the chemoattractant-mediated activation of NADPH oxidase (see Figs 1–3 and Table 1). Unlike for Bt_2cAMP and Bt_2cGMP , inhibition of agonist binding to formyl peptide receptors does not contribute to the inhibitory effects of sydnonimines on the respiratory burst as they slightly enhanced binding (see Table 2). Interestingly, interference of Bt_2cGMP with agonist binding was also reported for other peptide receptors [36]. As sydnonimines inhibited the fMet-Leu-Phe- and C5a-induced respiratory bursts to similar extents and as receptors for these agonists couple to G-proteins, we asked the question as to whether sydnonimines could have acted at the level of G-proteins. This is, however, unlikely as they did not inhibit GTP hydrolysis of G-proteins (see Table 2). Additionally, the lack of effect of sydnonimines on potentiation by guanosine 5'-*O*-(3-thiotriphosphate) of O_2^- formation in a cell-free system from HL-60 cells argues against interference of SIN-10 and SIN-1 with G-proteins and/or low molecular mass GTP-binding proteins. Furthermore, the resistance to inhibition by sydnonimines of the PMA-induced respiratory burst suggests that they did not inhibit protein kinase C (see Table 1). Moreover, the lack of effect of sydnonimines on arachidonic acid-induced O_2^- formation in a cell-free system from HL-60 cells argues against interference of these substances with a structural component of NADPH oxidase. Finally, SIN-1 and SNP effectively stimulated ADP-ribosylation of a 39-kDa protein in cytosol of HL-60 cells, but SIN-10 did not (see Fig. 4). This finding is in agreement with the notion that ADP-ribosylation of the 39-kDa protein depends on NO release [14, 15]. Thus, the dissociation of the effects of sydnonimines on the fMet-Leu-Phe-induced respiratory burst on one hand and on ADP-ribosylation of this protein on the other suggests that covalent modification of the 39-kDa substrate is unrelated to their inhibitory effects on O_2^- formation and O_2 consumption (see Figs 1–4 and Table 1).

SIN-1 is known to inhibit osteoclast functions in a cGMP-independent manner, but the effects of SIN-10 were not studied [18]. Recently, Bohn *et al.* [23] reported NO-independent effects of an analogue

of SIN-10 on vasodilation and suggested that sydnonimines may interfere with Ca^{2+} influx. Therefore, the effects of sydnonimines on fMet-Leu-Phe-induced rises in $[Ca^{2+}]_i$ in neutrophils were studied. Recently, we reported that SIN-1 up to 0.1 mmol/L did not inhibit fMet-Leu-Phe-induced rises in $[Ca^{2+}]_i$, but the effects of SIN-1 at higher concentrations could not be studied for methodological reasons [7]. In this study, we show that SIN-10 at concentrations as low as 10 μ mol/L substantially inhibited rises in $[Ca^{2+}]_i$ induced by fMet-Leu-Phe at a submaximally and maximally effective concentration (see Table 3). Thus, inhibition of rises in $[Ca^{2+}]_i$ may explain, at least in part, the inhibitory effects of SIN-10 on the chemoattractant-induced respiratory burst. This notion is supported by the finding that the sydnonimines did not inhibit the PMA-induced respiratory burst, a process which is independent of rises in $[Ca^{2+}]_i$ (see Table 1) [1, 2, 4]. Also in line with our findings are data showing that SIN-10 (10 μ mol/L) effectively inhibits thrombin-induced rises in $[Ca^{2+}]_i$ in human platelets [34]. Undoubtedly, the concentrations of SIN-10 required to inhibit the chemoattractant-induced respiratory burst are rather high (see Figs 1–3 and Table 1). However, there is ample evidence for the assumption that regulation of the respiratory burst *in vitro* and *in vivo* is quite different (for review see Ref. 2). Thus, it cannot be ruled out that the effects of sydnonimines are of clinical relevance. Similarly, the clinical importance of the effects of SIN-10 on other cell functions is not yet known [5, 7, 23, 34].

In conclusion, SIN-10 effectively inhibits the chemoattractant-induced respiratory burst in human neutrophils via a mechanism which is independent of NO release. Our present results are in accordance with other recent reports on NO-independent effects of sydnonimines [5, 7, 23, 34]. Thus, future studies dealing with the pharmacological effects of SIN-1 should include experiments with the so-called "prodrug" SIN-10. This sydnonimine is not inert but may modulate various cell functions even more effectively than its so-called "active metabolite", SIN-1.

Acknowledgements—The authors are grateful to Drs E. Böhme, B. Mayer, H. H. H. W. Schmidt and G. Schultz for helpful discussion, to E. Glaß and R. Bonnet for expert technical assistance and to Dr E. Keller, Blutbank des Deutschen Rotes Kreuzes Berlin, for supplying buffy coat. This work was supported by grants of the Deutsche Forschungsgemeinschaft.

REFERENCES

1. Rossi, The O_2^- -forming NADPH oxidase of the phagocytes: nature, mechanism of activation and function. *Biochim Biophys Acta* **853**: 65–89, 1986.
2. Seifert R and Schultz G, The superoxide-forming NADPH oxidase of phagocytes: an enzyme system regulated by multiple mechanisms. *Rev Physiol Biochem Pharmacol* **117**: 1–334, 1991.
3. Absolom DR, Basic methods for the study of phagocytosis. *Methods Enzymol* **132**: 95–180, 1986.
4. Sandborg RR and Smolen JE, Biology of disease: early biochemical events in leukocyte activation. *Lab Invest* **59**: 300–320, 1988.
5. Schröder H, Ney P, Woditsch I, Schrör K, Cyclic

- GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes. *Eur J Pharmacol* **182**: 211–218, 1990.
6. Ervens J, Schultz G and Seifert R, Differential inhibition and potentiation of chemoattractant-induced superoxide formation in human neutrophils by the cell-permeant analogue of cyclic GMP, $N^2,2'$ - O -dibutyl guanosine 3':5'-cyclic monophosphate. *Naunyn Schmiedbergs Arch Pharmacol* **343**: 370–376, 1991.
7. Wenzel-Seifert K, Ervens J and Seifert R, Differential inhibition and potentiation by cell-permeant analogues of cyclic AMP and cyclic GMP and NO-containing compounds of exocytosis in human neutrophils. *Naunyn Schmiedbergs Arch Pharmacol* **344**: 396–402, 1991.
8. Lad PM, Glovsky MM, Richards JH, Smiley PA and Backstrom B, Regulation of human neutrophil guanylate cyclase by metal ions, free radicals and the muscarinic cholinergic receptor. *Mol Immunol* **22**: 731–739, 1985.
9. Pryzwansky KB, Wyatt TA, Nichols H and Lincoln TM, Compartmentalization of cyclic GMP-dependent protein kinase in formyl-peptide stimulated neutrophils. *Blood* **76**: 612–618, 1990.
10. Wright CD, Kuipers PJ, Kobylarz-Singer D, Devall LJ, Klinkfuf BA and Weishaar RE, Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. *Biochem Pharmacol* **40**: 699–707, 1990.
11. Böhme E, Graf H and Schultz G, Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. *Adv Cyclic Nucleotide Res* **9**: 131–143, 1978.
12. Böhme E, Grossmann G and Spies C, Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation. *Eur Heart J* **4** (Suppl C): 19–24, 1983.
13. Feelisch M and Noack EA, Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. *Eur J Pharmacol* **139**: 19–30, 1987.
14. Brüne B and Lapetina EG, Activation of a cytosolic ADP-ribosyltransferase by nitric oxide-generating agents. *J Biol Chem* **264**: 8455–8458, 1989.
15. Dimmeler D and Brüne B, L-arginine stimulates an endogenous ADP-ribosyl-transferase. *Biochem Biophys Res Commun* **178**: 848–855, 1991.
16. Garg UC and Hassid A, Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. *Biochem Biophys Res Commun* **171**: 474–479, 1990.
17. Garg UC and Hassid A, Nitric oxide decreases cytosolic free calcium in Balb/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. *J Biol Chem* **266**: 9–12, 1991.
18. MacIntyre I, Zaidi M, Alam ASMT, Datta HK, Moonga BS, Lidbury PS, Hecker M and Vane JR, Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. *Proc Natl Acad Sci USA* **88**: 2936–2940, 1991.
19. Schmidt HHHW, Seifert R and Böhme E, Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B₄. *FEBS Lett* **244**: 357–360, 1989.
20. Wright CD, Mülsch A, Busse R and Osswald H, Generation of nitric oxide by human neutrophils. *Biochem Biophys Res Commun* **160**: 813–819, 1989.
21. Moncada S, Palmer RMJ and Higgs EA, Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. *Biochem Pharmacol* **38**: 1709–1715, 1989.
22. Feelisch M, Ostrowski J and Noack E, On the mechanism of NO release from sydnonimines. *J Cardiovasc Pharmacol* **14** (Suppl 11): S13–S22, 1989.
23. Bohn H, Beyerle R, Martorana PA and Schönafinger K, CAS 936, a novel sydnonimine with direct vasodilating and nitric oxide-donating properties: effects on isolated blood vessels. *J Cardiovasc Pharmacol* **18**: 522–527, 1991.
24. Seifert R, Burde and Schultz G, Lack of effect of opioid peptides, morphine and naloxone on superoxide formation in human neutrophils and HL-60 leukemic cells. *Naunyn Schmiedbergs Arch Pharmacol* **340**: 101–106, 1989.
25. Seifert R and Schultz G, Reversible activation of NADPH oxidase in membranes of HL-60 human leukemic cells. *Biochem Biophys Res Commun* **146**: 1296–1302, 1987.
26. Wenzel-Seifert K, Grünbaum L and Seifert R, Differential inhibition of human neutrophil activation by cyclosporins A, D and H: cyclosporin is a potent and effective inhibitor of formyl peptide-induced superoxide formation. *J Immunol* **147**: 1940–1946, 1991.
27. Seifert R, Serke S, Huhn D, Bessler WG, Hauschildt S, Metzger J, Wiesmüller K-H and Jung G, Incomplete functional differentiation of HL-60 leukemic cells by synthetic lipopeptides: partial inhibition by pertussis toxin of enhanced superoxide formation. *Eur J Biochem* **203**: 143–151, 1992.
28. Rosenthal W, Koseling D, Rudolph U, Kleuss C, Pallast M, Yajima M and Schultz G, Identification and characterization of the 35-kDa β subunit of guanine-nucleotide-binding proteins by an antiserum raised against transducin. *Eur J Biochem* **158**: 255–263, 1986.
29. Crapo JD, McCord JM and Fridovich I, Preparation and assay of superoxide dismutases. *Methods Enzymol* **53**: 382–393, 1978.
30. Marklund S and Marklund G, Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *Eur J Biochem* **47**: 469–474, 1974.
31. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**: 265–275, 1951.
32. Johnson RA and Walseth TF, The enzymatic preparation of [α -³²P]ATP, [α -³²P]GTP, [³²P]cAMP, and [³²P]cGMP, and their use in the assay of adenylate and guanylate cyclases and cyclic nucleotide phosphodiesterases. *Adv Cyclic Nucleotide Res* **10**: 135–167, 1979.
33. Cassel D and Pfeuffer T, Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. *Proc Natl Acad Sci USA* **75**: 2669–2673, 1978.
34. Baumann I and Baumann J, Molsidomine, the novel sydnonimine CAS 936 and their metabolites inhibit intracellular free calcium in stimulated human platelets. *Naunyn Schmiedbergs Arch Pharmacol* **345** (Suppl): R56, 1992.
35. Rubanyi GM, Ho EH, Cantor EH, Lumma WC and Botelho LHP, Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. *Biochem Biophys Res Commun* **181**: 1392–1397, 1991.
36. Robberecht P, Deschodt-Lanckman M, Woussen-Colle M-C, de Neef P, Camus JC and Christophe J, Butyryl derivatives of cyclic GMP interfere with the biological and the immunological properties of the pancreatico-gastrin family of peptides. *Mol Pharmacol* **17**: 268–274, 1980.